MedPath

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

Phase 1
Recruiting
Conditions
Metastatic or Locally Advanced Unresectable Solid Tumors
Interventions
Registration Number
NCT05396833
Lead Sponsor
EMD Serono Research & Development Institute, Inc.
Brief Summary

This is an open-label, multicenter, clinical study conducted in multiple parts to establish the safety, tolerability, Pharmacokinetic/Pharmacodynamic (PK/PD) profile, maximum tolerated dose (MTD) combinations (if observed) and recommended dose for expansion (RDE) combination for tuvusertib in combination with lartesertib (in Part A1), food effect on the PK of lartesertib as monotherapy followed by treatment with tuvusertib in combination with lartesertib in participants with specific tumor types (in Part A1.1), relative bioavailability of a tuvusertib tablet formulation vs capsule formulation followed by treatment with tuvusertib (capsule) in combination with lartesertib in participants with specific tumor types (in Part A1.2), safety/tolerability and early signs of clinical activity of tuvusertib (capsule)and lartesertib in combination in participants with prostate cancer harboring loss of function (LoS) mutation in the gene ATM based on historic data collected prior to prescreening in circulating tumor (ct) DNA (liquid biopsies) or tumor biopsies (in Part A2), safety/tolerability and early signs of clinical activity of tuvusertib and lartesertib in combination in participants with endometrial cancer harboring LoS mutation(s) in the gene ARID1A based on historic data collected prior to prescreening in ctDNA (liquid biopsies) or tumor biopsies (in Part A3), the relative bioavailability of a tuvusertib tablet formulation (TF1, test) compared to a capsule formulation (reference) will also be investigated (in Part A2/A3), and identify a potential set of MTD combinations, and establish the RDE for the combination of tuvusertib and avelumab in participants with metastatic or locally advanced unresectable solid tumors (in Part B1).

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
123
Inclusion Criteria
  • Parta A1, A1.1, A1.2, A2, A3, and A2/3: Participants with metastatic or locally advanced unresectable solid tumors refractory to standard therapy or for which no standard therapy is judged appropriate by the Investigator, which may convey clinical benefit, or who cannot tolerate standard of care treatment
  • Parts A1.1 and A1.2: Triple negative breast cancer, epithelial ovarian cancer, castrate resistant prostate cancer, urothelial cancer, endometrial cancer, and colorectal cancer independent of mutation status.
  • Part A2: Participants with advanced prostate cancer whose tumor carries a genetic loss of function (LoF) mutation(s) in the gene ataxia telangiectasia mutated (ATM).

No more than 3 prior lines of therapy for castrate resistant disease. Prior therapy must have included a taxane and a novel antiandrogen (example [e.g.] enzalutamide).

  • Part A3: Participants with advanced endometrial cancer whose tumor carries a genetic LoF mutation(s) in the gene AT-rich interaction domain 1A (ARID1A).

Prior therapy must have included a platinum agent. Prior therapy must also have included a checkpoint inhibitor if the participant has mismatch repair (MMR)-deficient endometrial cancer. - Note for Parts A2/A3: Participants with ATM LoF mutated prostate cancer and ARID1A LoF mutated endometrial cancer should be prioritized to the respective expansion arms instead of being enrolled in Part A1.1. The presence of ATM and ARID1A LoF mutations will be determined according to historic data collected prior to prescreening, generated by an assay with appropriate regulatory status, in either tumor or liquid biopsy. The Sponsor will confirm that mutations certified by historic data fulfil this definition.

  • Participants with eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, with estimated life expectancy of at least 3 months
  • Adequate hematological, hepatic, and renal function as defined in the protocol
  • Other protocol defined inclusion criteria could apply
Exclusion Criteria
  • Participants with any condition, including any uncontrolled disease state other than with metastatic or locally advanced unresectable solid tumors, that in the Investigator's opinion constitutes an inappropriate risk or a contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation
  • Participants with a known additional malignancy that is progressing and/or requires active treatment
  • Participants with carcinomatous meningitis are excluded regardless of clinical stability
  • Participants with serious gastrointestinal bleeding within 3 months, refractory nausea and vomiting, uncontrolled diarrhea, known malabsorption, significant small bowel resection or gastric bypass surgery, use of feeding tubes, other chronic gastrointestinal disease, and/or other situations that may preclude adequate absorption of oral medications
  • Participants with organ transplantation, including allogeneic stem cell transplant
  • Other protocol defined exclusion criteria could apply

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Part A1: Tuvusertib and LartesertibLartesertib-
Part A2: Tuvusertib and LartesertibTuvusertibATM in prostate cancer (Part A2)
Part A2: Tuvusertib and LartesertibLartesertibATM in prostate cancer (Part A2)
Part A3: Tuvusertib and LartesertibTuvusertibARID1A in endometrial cancer
Part B1: Tuvusertib and AvelumabTuvusertib-
Part A1.2: Tuvusertib and LartesertibTuvusertibRelative Bioavailability Assessment of Tuvusertib Tablet (TF1) vs Capsule Followed by Treatment with Tuvusertib in Combination with Lartesertib
Part A1.2: Tuvusertib and LartesertibLartesertibRelative Bioavailability Assessment of Tuvusertib Tablet (TF1) vs Capsule Followed by Treatment with Tuvusertib in Combination with Lartesertib
Part A1.1: Tuvusertib and LartesertibLartesertibAssessment of the Effect of Food (Low-fat Meal) on the PK of M4076 Monotherapy Followed by Treatment with M1774 in Combination with M4076
Part A3: Tuvusertib and LartesertibLartesertibARID1A in endometrial cancer
Part A2/A3: Tuvusertib and LartesertibLartesertibTablet formulation (TF1, test) compared to a capsule formulation (reference)
Part A2/A3: Tuvusertib and LartesertibTuvusertibTablet formulation (TF1, test) compared to a capsule formulation (reference)
Part A1.1: Tuvusertib and LartesertibTuvusertibAssessment of the Effect of Food (Low-fat Meal) on the PK of M4076 Monotherapy Followed by Treatment with M1774 in Combination with M4076
Part A1: Tuvusertib and LartesertibTuvusertib-
Part B1: Tuvusertib and AvelumabAvelumab-
Primary Outcome Measures
NameTimeMethod
Part B1: Number of Participants with AEs and Treatment-Related AEsBaseline up to 18 months
Part A1.2: Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero Extrapolated to Infinity [Frel(AUC0-inf)] of Tuvusertib Test Treatment Compared to Tuvusertib Reference TreatmentDay -4 up to Period 1 Day 1
Part A2/A3: Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero to Last Quantifiable Concentration [Frel(AUC0-t)] of Tuvusertib Test Treatment Compared to Tuvusertib Reference TreatmentDay -4 up to Period 1 Day 1
Part A1: Number of Participants With Adverse Events (AEs) and Treatment-Related AEsBaseline up to 18 months
Part A1.1: PK Plasma Concentration of Lartesertib Under Fed and Fasted ConditionsDay -1 up to Period 1 Day 1
Part B1: Number of Participants with Dose-Limiting Toxicities (DLTs) During the DLT Evaluation PeriodDay 1 up to Day 28
Part A2/A3: Number of Participants With AEs and Treatment-Related AEsBaseline up to 18 months
Part A2/A3: Objective Response according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by InvestigatorUp to 18 months after first dose administration
Part A1.2: Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero to Last Quantifiable Concentration [Frel(AUC0-t)] of Tuvusertib Test Treatment Compared to Tuvusertib Reference TreatmentDay -4 up to Period 1 Day 1
Part A1.2: Ratio Maximum Observed Plasma Concentration (Ratio[Cmax]) of Tuvusertib Test Treatment Compared to Tuvusertib Reference TreatmentDay -4 up to Period 1 Day 1
Part A2/A3: Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero Extrapolated to Infinity [Frel(AUC0-inf)] of Tuvusertib Test Treatment Compared to Tuvusertib Reference TreatmentDay -4 up to Period 1 Day 1
Part A2/A3: Ratio Maximum Observed Plasma Concentration (Ratio[Cmax]) of Tuvusertib Test Treatment Compared to Tuvusertib Reference TreatmentDay -4 up to Period 1 Day 1
Part B1: Change From Baseline in PD BiomarkerPre-dose up to approximately 1 month

The PD biomarker of histone variant will be measured by flow cytometry.

Part A1: Number of Participants With Dose-Limiting Toxicities (DLTs) During the DLT Evaluation PeriodDay 1 up to Day 28
Part A1: Change From Baseline in Pharmacodynamic (PD) BiomarkerPre-dose up to approximately 1 month

The PD biomarker of histone variant will be measured by flow cytometry.

Secondary Outcome Measures
NameTimeMethod
Part A1 and B1: Objective Response (OR) According to Response Evaluation Criteria in Solid Tumor (RECIST) v1.1Up to 18 months after first dose administration
Part B1: Number of Participants with Any Positive Anti-Drug Antibody (ADA) of AvelumabBaseline up to 18 months
Parts A1.1, A1.2 and A2/3: Number of Participants With AEs and Treatment-Related AEsBaseline up to 18 months
Part A2/A3: Time to Reach Maximum Plasma Concentration (tmax) of TuvusertibDay -4 up to Period 1 Day 1
Part A1 and B1: Number of Participants with Clinically Significant Abnormalities in Digital Electrocardiogram (ECG) MeasuresBaseline up to 18 months
Part A1: Pharmacokinetic (PK) Plasma Concentration of Tuvusertib and LartesertibPre-dose up to approximately 6 months
Parts A1.2 and B1: Pharmacokinetic (PK) Plasma Concentration of TuvusertibPre-dose up to approximately 6 months
Part B1: Pharmacokinetic (PK) Serum Concentration of AvelumabPre-dose up to approximately 18 months
Part A1.1: PK Plasma and Urine Concentration of Lartesertib Under Fed and Fasted ConditionsDay -1 up to Period 1 Day 1
Part A2/A3: Duration of Response according to RECIST v1.1Up to 18 months after first dose administration
Part A2/A3: Clinical benefit (either OR or stable disease for 6 months or more) according to RECIST v1.1.Up to 18 months after first dose administration
Part A2/A3: Progression Free Survival according to RECIST v1.1 modified according to the Prostate Cancer Working Group 3 (PCWG-3), assessed by InvestigatorUp to 18 months after first dose administration

Trial Locations

Locations (20)

Providence Medical Foundation

🇺🇸

Santa Rosa, California, United States

University of Miami School of Medicine

🇺🇸

Miami, Florida, United States

Augusta University - formerly Georgia Regents University

🇺🇸

Augusta, Georgia, United States

The University of Kansas Medical Center Research Institute, Inc.

🇺🇸

Kansas City, Kansas, United States

Carolina Urologic Research Center

🇺🇸

Myrtle Beach, South Carolina, United States

Mary Crowley Cancer Research Centers

🇺🇸

Dallas, Texas, United States

University of Texas M. D. Anderson Cancer Center - Partner

🇺🇸

Houston, Texas, United States

NEXT Oncology

🇺🇸

San Antonio, Texas, United States

Princess Margaret Cancer Centre

🇨🇦

Toronto, Canada

Seoul National University Bundang Hospital

🇰🇷

Seongnam-si, Korea, Republic of

Severance Hospital, Yonsei University Health System - Division of Infectious Diseases

🇰🇷

Seoul, Korea, Republic of

Asan Medical Center

🇰🇷

Seoul, Korea, Republic of

Samsung Medical Center

🇰🇷

Seoul, Korea, Republic of

The Catholic University of Korea, Seoul St. Mary's Hospital

🇰🇷

Seoul, Korea, Republic of

Korea University Guro Hospital

🇰🇷

Seoul, Korea, Republic of

Hospital QuironSalud Barcelona - Next Oncology

🇪🇸

Barcelona, Spain

Hospital Clinic de Barcelona - Servicio de Oncologia

🇪🇸

Barcelona, Spain

Hospital Universitario Fundacion Jimenez Diaz - START Madrid FJD - Oncology Phase I

🇪🇸

Madrid, Spain

Centro Integral Oncologico Clara Campal - Unidad de Fase I-Oncologica

🇪🇸

Madrid, Spain

Hospital Universitario Quironsalud Madrid - NEXT Oncology

🇪🇸

Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath